(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)phenol for Neuropathic Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetic neuropathic pain, particularly diabetic peripheral neuropathy, are inadequate due to the limited effectiveness of existing medications, which often come with significant side effects or are ineffective in neuropathic pain models.
Innovation Solution
The use of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol, which acts as a centrally active analgesic with a dual mode of action as a µ-opioid receptor agonist and noradrenaline uptake inhibitor, providing effective pain relief with reduced opioid-like side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gabapentin is used for treatment, then neuropathic pain is treated, but effectiveness is relatively low and significant doses are required
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of gabapentin to create (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol, which has improved analgesic potency. The structural modification changes the molecular parameters to achieve better binding affinity at lower concentrations, resolving the contradiction between effectiveness and required dose.
Solution Approach 2:
The invention applies local quality by introducing specific stereochemical configuration (1R,2R) and functional groups (dimethylamino, phenol) at particular positions in the molecule. This localized structural optimization enhances the drug's interaction with neural targets, improving effectiveness without requiring proportionally higher doses.
2Reliability
If morphine is used for treatment, then neuropathic pain is treated, but side effect profile is problematic
Solution Approach 1:
The patent extracts the essential analgesic property from morphine while removing its harmful side effects. By designing a completely different molecular structure ((1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol) that achieves pain relief through alternative mechanisms, the invention separates the beneficial effect from the harmful side effects associated with traditional opioids.
Solution Approach 2:
The invention creates a composite molecular structure combining features of different chemical classes (amine, phenol, terpene-like scaffold) to achieve multifunctional activity. This composite structure provides analgesic effectiveness through multiple mechanisms while avoiding the specific side effect profile of pure opioid compounds.
3Adaptability or versatility
If conventional pain treatments are used, then nociceptive pain is treated, but neuropathic pain is not effectively treated
Solution Approach 1:
The patent creates a compound with universal analgesic activity that works across different pain types. The (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol molecule is designed to interact with multiple neural targets and pathways, providing effectiveness in both nociceptive and neuropathic pain models, thus resolving the limitation of conventional treatments.
Solution Approach 2:
The invention uses parameter changes in molecular structure to enhance adaptability to different pain mechanisms. By optimizing lipophilicity, molecular size, and functional group arrangement, the compound achieves broad spectrum analgesic activity while maintaining high effectiveness specifically in neuropathic pain conditions.
Data Source
AI summary
The invention relates to the use of 1-phenyl-3-dimethylamino-propane compounds for the production of pharmaceuticals for the treatment of neuropathic, preferably of polyneuropathic pain, further preferably of diabetic neuropathic pain, preferably diabetic peripheral neuropathic pain, further preferably for the treatment of diabetic peripheral neuropathy.